The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / November / The New Front Line of STI Diagnosis
Omics Precision medicine Research and Innovations Molecular Pathology

The New Front Line of STI Diagnosis

Point-of-care and at-home tests are expanding access while creating new challenges for reporting and public health surveillance

By Nikolina Babic, Sheldon Campbell, Kate Crawford 11/18/2026 Discussion 5 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll

Share

Objective:

The article describes point-of-care (POC) testing for sexually transmitted infections, including available assays, potential benefits, and the role of laboratory professionals in implementation.

Approach:
  • Testing model: POC tests are performed close to the patient, outside the traditional clinical laboratory, and typically provide results within minutes to an hour.
  • Available tests: Rapid antibody and antigen-antibody tests for syphilis and HIV have been used for years and can provide results in less than 30 minutes. Newer FDA-cleared, CLIA-waived molecular assays detect chlamydia and gonorrhea in approximately 20 minutes; some newer platforms also test for Mycoplasma genitalium and Trichomonas vaginalis.
  • Implementation: Pathologists and laboratory professionals contribute to test selection, implementation, quality assurance, and oversight.
Key Findings:
  • Results available during the same encounter can support diagnosis and treatment without depending on a later follow-up visit.
  • The article describes potential benefits including reduced loss to follow-up, less reliance on empiric treatment, and improved access for people facing barriers to conventional testing.
  • Accurate rapid testing may reduce reliance on syndromic treatment, support antimicrobial stewardship, and limit unnecessary antibiotic exposure.
  • POC tests for herpes simplex virus and human papillomavirus are not yet available.
Interpretation:

The article describes POC testing as a complement to centralized laboratory services, particularly where loss to follow-up is common or rapid treatment is important.

Limitations:
  • Molecular platforms may involve substantial cost and operational complexity.
  • Some assays have restrictions on specimen types, including limited approval for extragenital testing.
  • CLIA-waived tests still require staff training, competency assessment, and quality control.
  • Workflow, staffing, and testing volume may make implementation impractical in some settings.
Conclusion:

The article states that POC STI testing requires appropriate training, quality controls, and integration into health care systems.

Sources:
  • Article context provided by the user

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Nikolina Babic

Nikolina Babic is Board-certified clinical chemist and Professor of Pathology and Laboratory Medicine, Medical University of South Carolina.

More Articles by Nikolina Babic

Sheldon Campbell

Sheldon Campbell is Professor of Laboratory Medicine, Yale School of Medicine, and Director of Clinical Laboratories, VA Connecticut Healthcare System.

More Articles by Sheldon Campbell

Kate Crawford

Kate Crawford is Acting Assistant Professor, Department of Laboratory Medicine and Pathology, University of Washington.

More Articles by Kate Crawford

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.